UBS Group AG Sells 73,593 Shares of Neurogene Inc. $NGNE

UBS Group AG trimmed its holdings in Neurogene Inc. (NASDAQ:NGNE) by 32.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,123 shares of the company’s stock after selling 73,593 shares during the quarter. UBS Group AG owned about 0.99% of Neurogene worth $3,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. BNP Paribas Financial Markets increased its stake in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after acquiring an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in Neurogene during the 3rd quarter valued at about $187,000. Finally, Brevan Howard Capital Management LP bought a new stake in Neurogene during the 3rd quarter valued at about $223,000. 52.37% of the stock is currently owned by institutional investors.

Insider Activity at Neurogene

In related news, CFO Christine Mikail Cvijic sold 9,600 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total value of $300,000.00. Following the sale, the chief financial officer owned 93,640 shares in the company, valued at approximately $2,926,250. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider owned 30,497 shares in the company, valued at $634,642.57. This represents a 18.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,442 shares of company stock worth $525,622 in the last 90 days. 11.68% of the stock is currently owned by corporate insiders.

Neurogene Price Performance

Shares of NASDAQ NGNE opened at $27.71 on Monday. The firm’s 50-day moving average price is $24.65 and its 200-day moving average price is $21.91. The company has a market cap of $437.87 million, a PE ratio of -6.09 and a beta of 1.69. Neurogene Inc. has a 52-week low of $14.65 and a 52-week high of $37.27.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). As a group, equities research analysts anticipate that Neurogene Inc. will post -5.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NGNE. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Lifesci Capital began coverage on shares of Neurogene in a research note on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective for the company. Canaccord Genuity Group reduced their price objective on shares of Neurogene to $180.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Finally, Guggenheim began coverage on shares of Neurogene in a research note on Tuesday, April 28th. They set a “buy” rating and a $69.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $74.17.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.